COVID-19 vaccine

The Russian Direct Investment Fund: Sputnik V vaccine approved in Paraguay

Friday, January 15, 2021 - 3:29pm

MOSCOW, Jan. 15, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of the Republic of Paraguay.

Key Points: 
  • MOSCOW, Jan. 15, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of the Republic of Paraguay.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
    "Registration of Sputnik V vaccine in Paraguay proves the increasing interest of Latin American countries in a safe and effective Russian vaccine against coronavirus.
  • Sputnik V has a number of key advantages:
    Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.
  • The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine and Venezuela; the process to approve the vaccine in the EU has been initiated.

Praktice AI's Digital COVID Vaccine Assistant for Health Systems is autonomously navigating vaccine seekers 24x7

Friday, January 15, 2021 - 2:23pm

BOSTON, Jan. 15, 2021 /PRNewswire/ -- Praktice AI , the AI-powered Digital care navigation company, released the COVID-19 vaccine care navigation tool in December 2020, to help health systems autonomously navigate vaccine seekers through eligibility checks, appointment booking, and post-vaccination support, 24x7.

Key Points: 
  • BOSTON, Jan. 15, 2021 /PRNewswire/ -- Praktice AI , the AI-powered Digital care navigation company, released the COVID-19 vaccine care navigation tool in December 2020, to help health systems autonomously navigate vaccine seekers through eligibility checks, appointment booking, and post-vaccination support, 24x7.
  • The solution is deployed at various Community care centers, health systems, and physician groups.
  • As the health systems are inundated with calls related to vaccine inquiries, in some cases 4 - 5 times the usual call volumes, deploying the COVID digital assistant by Praktice has been freeing up the care teams, by automating 80% of these pathways through AI.
  • "As managing the current vaccine administration is a once-in-a-century challenge, it's very essential for health systems to shun the conventional digital solutions and adopt a fully plug-and-play care navigation technology," said Srinath Akula, co-founder, and chief executive officer, Praktice.

COVID-19 vaccines: Common solution, not competition

Friday, January 15, 2021 - 2:01pm

After China's official approval, over a dozen countries from different continents signed purchase agreements with China for the vaccine.

Key Points: 
  • After China's official approval, over a dozen countries from different continents signed purchase agreements with China for the vaccine.
  • Since the initial outbreak, scientists around the world have been working to develop an effective vaccine.
  • Various approaches have been adopted, such as mRNA vaccines, inactivated vaccines and adenovirus vector vaccines.
  • Faced with the virus, humanity should work together to seek solutions to this common challenge.

Vault Launches On-Demand Turnkey COVID-19 Vaccine Administrative Services

Friday, January 15, 2021 - 2:00pm

Vault works with state and local governments to build mass vaccination sites to provide vaccinations to thousands of residents every day.

Key Points: 
  • Vault works with state and local governments to build mass vaccination sites to provide vaccinations to thousands of residents every day.
  • Vault partnered with local and state governments across the US on full service PCR and antigen testing programs, notably with the state of Minnesota including at-home, on-site and pop-up testing events.
  • Vault will replicate the logistics of their many on-site COVID testing sites to create micro-to-mega vaccination sites to safely and swiftly administer the COVID-19 vaccine across the country.
  • Vault is already working with state partners to develop vaccination programs and has the capabilities to work nationwide immediately.

VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

Friday, January 15, 2021 - 1:00pm

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBIs prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBIs prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier.
  • In this Phase 4 study, our 3-antigen HBV vaccine once again demonstrated robust immunogenicity with no additional safety signals observed, said Dr. Francisco Diaz-Mitoma, VBIs Chief Medical Officer.
  • Prior to market release in Israel, batches of VBIs vaccine are tested against a reference vaccine batch that has been assessed in a clinical trial.
  • VBIs lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program.

Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine

Friday, January 15, 2021 - 1:00pm

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).

Key Points: 
  • BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).
  • Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.
  • In France, monitoring the safety of drugs, particularly vaccines, is carried out by the ANSM and the CRPVs.
  • Synapse Medicine has been working in collaboration with these health institutions for the past 18 months on a research project aiming to support the management of pharmacovigilance cases.

Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine

Friday, January 15, 2021 - 8:00am

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).

Key Points: 
  • BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM).
  • Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.
  • In France, monitoring the safety of drugs, particularly vaccines, is carried out by the ANSM and the CRPVs.
  • Synapse Medicine has been working in collaboration with these health institutions for the past 18 months on a research project aiming to support the management of pharmacovigilance cases.

Cureduchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollout

Thursday, January 14, 2021 - 11:39pm

NEWPORT BEACH, Calif., Jan. 14, 2021 /PRNewswire/ --CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne community needs.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 14, 2021 /PRNewswire/ --CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout and Duchenne community needs.
  • CureDuchenne is the ideal conduit for providing the Duchenne community with critical education, advocacy and support.
  • This COVID-19 vaccine initiative rollout continues to cement its leadership position with a multi-step approach prioritizing vaccine education, greater access and support for the global Duchenne community:
    CureDuchenne is hosting a webinar on January 22 , 2021 entitled, "COVID-19 Vaccines - What the Duchenne Community Needs to Know", about the COVID-19 vaccine rollout and its impact on those living with Duchenne.
  • As we work with states and local officials, we look forward to advocating on behalf of the entire Duchenne community while the vaccine rollout progresses.

Fragrance Creators Association Launches COVID-19 State Vaccine Tracker

Thursday, January 14, 2021 - 11:14pm

WASHINGTON, Jan. 14, 2021 /PRNewswire/ --Fragrance Creators Association launched today its COVID-19 State Vaccine Tracker, which provides its member companies across the fragrance value chain with updated guidance on states' vaccine rollouts.

Key Points: 
  • WASHINGTON, Jan. 14, 2021 /PRNewswire/ --Fragrance Creators Association launched today its COVID-19 State Vaccine Tracker, which provides its member companies across the fragrance value chain with updated guidance on states' vaccine rollouts.
  • The COVID-19 State Vaccine Tracker is the latest resource from Fragrance Creators as it delivers meaningful education opportunities and support for members, including December 2020 webinar, "COVID-19 Vaccine Distribution and Employment Law Implications," featuring experts from Arent Fox.
  • Fragrance Creators Association is the principal fragrance trade association.
  • Fragrance Creators produces The Fragrance Conservatory ,thecomprehensive, public digital resource for high-quality information about fragrance.

COVID-19 Vaccine: Making the Invisible Visible

Thursday, January 14, 2021 - 9:40pm

WILMINGTON, N.C., Jan. 14, 2021 /PRNewswire/ --If COVID-19 was the invisible enemy, the COVID-19 vaccine is the invisible cure.

Key Points: 
  • WILMINGTON, N.C., Jan. 14, 2021 /PRNewswire/ --If COVID-19 was the invisible enemy, the COVID-19 vaccine is the invisible cure.
  • With the CastleBranch Real Vaccination ID card, individuals will have third-party verified, physical evidence of their vaccination status.
  • Cards will include built-in fraud-prevention measures, affording them greater freedom of movement a passport to businesses, schools, transportation, events and more.
  • And it's how we will continue to stand with you as we have before, during and after the COVID-19 pandemic."